Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neuroblastoma 2Glioblastoma 2Recurrence 1Melanoma 1Medulloblastoma 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

neratinib 1fludarabine 1famitinib 1encorafenib 1camrelizumab 1Valproic Acid 1Taxes 1TPI-287 1Sodium Selenite 1Nivolumab 1Ifosfamide 1Gemcitabine 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Disease Progression × TPI-287 × Clear all
NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡